- Product Details
Keywords
- 220127-57-1
- Imatinib mesylate
Quick Details
- ProName: Imatinib mesylate 220127-57-1
- CasNo: 220127-57-1
- Molecular Formula: C30H35N7O4S
- ProductionCapacity: Metric Ton/Day
- Purity: 99%
- LimitNum: 0 Metric Ton
Superiority
GLIVEC;GLEEVEC;IMATINIB METHANESULFONATE;CGP-57148B;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate;4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate;STI-571;IMATINIB BASE(IMA-3)
Details
Imatinib mesylate Chemical Properties
mp 214-224°C
storage temp. -20°C Freezer
CAS DataBase Reference 220127-57-1(CAS DataBase Reference)
Safety Information
Hazardous Substances Data 220127-57-1(Hazardous Substances Data)
MSDS Information
Imatinib mesylate Usage And Synthesis
a small-molecule inhibitor Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.
Chemical Properties Off-White Solid
Usage A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
Usage Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
Usage Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
Usage echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis